BofA lowered the firm’s price target on Incyte to $67 from $69 and keeps a Neutral rating on the shares after the company presented Phase 2 data for povorcitinib in PN and ruxolitinib cream in mild-to-moderate HS at the AAD meeting. The firm thinks povorcitinib’s results in PN are “encouraging,” but looks for additional color on the commercial opportunity based on initial key opinion leader feedback, so it has lowered its pipeline value to $2.5B from $3B, resulting in its lower price target for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INCY:
- Incyte to hold a conference call
- Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
- Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
- Incyte says FDA grants priority review for axatilimab
- Block upgraded, Rivian downgraded: Wall Street’s top analyst calls